stars 1 stars 2 stars 3

Kode Biotech Limited is a private company established in 1996 to commercialise and license Kode™ Technology. Kode Biotech Ltd is the licensor of existing, and developer of new Kode™ Technology. Kode™ Technology is a multifunctional 'nanotechnology paint' that is the easiest, fastest, most versatile, and controllable platform for temporary modification of any cell, virus, and/or surface (biological or non-biological) within a few hours enabling new and better therapeutics, diagnostics and consumer products. No special equipment or processes are required with Kode™ Technology as modification happens spontaneously on contact without affecting vitality or functionality. Rapid biosurface modification offers significant opportunities for innovation and product improvement in virtually every area of the life sciences. In 2015, Kode Biotech Ltd was named as New Zealand's "Supreme Innovator of the Year" for its contribution to an anti-cancer treatment that is currently in Phase1/2a clinical trials

Kode Biotech Questions

The Kode Biotech annual revenue was $1 million in 2026.

Stephen Henry is the CEO and Managing Director of Kode Biotech.

2 people are employed at Kode Biotech.

Kode Biotech is based in Auckland, Auckland.

The NAICS codes for Kode Biotech are [54, 5417, 54171, 541, 541713].

The SIC codes for Kode Biotech are [87, 873].

Top Kode Biotech Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users